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Abstract Human S100A12 (extracellular newly identified
RAGE (receptor for advanced glycosylation end products)-
binding protein), a new member of the S100 family of EF-hand
calcium-binding proteins, was chemically synthesised using
highly optimised 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylur-
onium hexafluorophosphate/tert-butoxycarbonyl in situ neutrali-
sation solid-phase chemistry. Circular dichroism studies
indicated that CaCl2 decreased the helical content by 27%
whereas helicity was marginally increased by ZnCl2. The
propensity of S100A12 to dimerise was examined by electrospray
ionisation time-of-flight mass spectrometry which clearly demon-
strated the prevalence of the non-covalent homodimer (20 890
Da). Importantly, synthetic human S100A12 in the nanomolar
range was chemotactic for neutrophils and macrophages in
vitro. ß 2001 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The S100 family is comprised of closely related low molec-
ular weight (10^14 kDa) acidic calcium-binding proteins
(CaBPs), which have been associated with a range of disorders
including atherosclerosis, in£ammatory bowel disease, rheu-
matoid arthritis, delayed-type hypersensitivity, Alzheimer’s
disease, and cancer [1]. Myeloid S100A8 (migration inhibitory
factor related protein 8 (MRP8), calgranulin A) [2], S100A9
(MRP14, calgranulin B) [2] and S100A12 (calgranulin C, p6,
CAAF1, CGRP) [3,4] are found at in£ammatory foci and
may be released by activated neutrophils (PMN) or mono-
cytes/macrophages. High plasma levels of A8 and A9 are in-
dicators of in£ammatory disease [5] and the proteins have
anti-microbial properties in vitro [1,6,7]. Recent evidence in-
dicates that bovine S100A12, a relatively new member of the
S100 family, is a ligand for the receptor for advanced glyco-
sylated end products (RAGE) expressed by macrophages, en-
dothelial cells and lymphocytes [8]. It is proposed that RAGE
may act as the central cell surface receptor mediating the
cellular responses of S100 proteins at in£ammatory sites, re-
sulting in propagation of the host response by increased
monocyte recruitment and cellular activation [8].
Human S100A12 consists of 91 amino acid residues, has
two EF-hands and a predicted C-terminal zinc-binding site
(His^Xaa^Xaa^Xaa^His) [9]. The EF-hand structural motif
consists of a loop £anked by K-helices (helix^loop^helix),
which together form a single EF-hand calcium-binding site
[10]. S100A12 has 40% (65%) and 46% (70%) sequence ho-
mology (similarity) with the related myeloid-associated S100
proteins, S100A8 and S100A9 (Fig. 1), and a high degree of
amino acid sequence identity (59%) with the novel murine
chemotactic factor, CP10 (now known as murine S100A8),
previously described by us [11,12]. The role of homo- and
hetero-dimerisation and interactions with calcium and zinc
ions in the functional properties of these S100 proteins is
not well understood [13^15]. Nuclear magnetic resonance
(NMR) studies with calcyclin revealed its non-covalent anti-
parallel homodimeric tertiary structure, and non-covalent ho-
modimerisation was con¢rmed in the recently reported crystal
structure of psoriasin (S100A7) [16,17].
To further investigate the role of human S100A12 in in£am-
mation, mg quantities of the protein were ¢rst required. De-
velopment of a reliable recombinant expression system for
S100A12 was di⁄cult to establish, and we undertook the total
chemical synthesis of human S100A12 using highly optimised
2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexa-
£uorophosphate (HBTU)/tert-butoxycarbonyl (Boc) in situ
neutralisation chemistry to provide rapid access to this pro-
tein. Here we report the synthesis, puri¢cation and potent
chemotactic activity of human S100A12. The use of electro-
spray ionisation time-of-£ight mass spectrometry (ESI-TOF
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MS) to probe non-covalent protein^protein interactions of
human S100A12 is also described.
2. Materials and methods
2.1. Materials
Boc-(L)-amino acids were obtained from Novabiochem (San Diego,
CA, USA) and the Peptide Institute (Osaka, Japan). Boc-amino acid-
Pam-resin was purchased from Applied Biosystems (Foster City, CA,
USA). Dichloromethane (DCM), diisopropylethylamine (DIEA),
N,N-dimethylformamide (DMF) and tri£uoroacetic acid (TFA) were
obtained from Auspep (Melbourne, Australia). High performance liq-
uid chromatography (HPLC) grade acetonitrile was purchased from
BDH chemicals. HBTU was purchased from Richelieu Biotechnolo-
gies (Quebec, Canada).
2.2. Solid-phase synthesis of S100A12
Human S100A12 (TKLEEHLEGIVNIFHQYSVRKGHFDTLSK-
GELKQLLTKELANTIKNIKDKAVIDEIFQGLDANQDEQVDF-
QEFISLVAIALKAAHYHTHKE) was manually synthesised stepwise
using highly optimised in situ neutralisation/HBTU activation proto-
cols for Boc/benzyl chemistry as previously described [18,19]. The
synthesis was performed on Boc-Glu(O-Bzl)-Pam resin using the fol-
lowing NK- and side-chain protected amino acids: Boc-Arg(4-toluene-
sulphonyl), Boc-Asp(O-cyclohexyl)-OH, Boc-Asn(xanthyl)-OH, Boc-
Glu(O-cyclohexyl)-OH, Boc-Gln(xanthyl)-OH, Boc-His(Nim-2,4-dini-
trophenyl)-OH, Boc-Lys(NO-2-chlorobenzyloxycarbonyl)-OH, Boc-
Ser(O-benzyl)-OH, Boc-Thr(O-benzyl)-OH, and Boc-Tyr(2-bromo-
benzyloxycarbonyl)-OH. Each residue was coupled for 10 min and
coupling e⁄ciencies determined by the quantitative ninhydrin assay
[28]. If ¢rst coupling yields were below approximately 99.2%, re-cou-
pling was carried out until satisfactory yields were achieved. The
average yield of chain assembly was 99.6% per residue. Partial depro-
tection of the peptide was carried out on the resin prior to HF cleav-
age. Dinitrophenyl groups were removed by thiolysis (10% DIEA,
20% L-mercaptoethanol and 70% DMF). The N-terminal Boc group
was removed with TFA. The resin was then washed with DMF fol-
lowed by DCM and then dried under a nitrogen atmosphere. Side-
chain protecting groups were removed and the peptide cleaved from
the resin by treatment with anhydrous HF/p-cresol (9:1) for 60 min at
35 to 0‡C. After evaporation of the HF, the crude peptide was pre-
cipitated, washed with diethyl ether, dissolved in 50% aqueous aceto-
nitrile and lyophilised following aqueous dilution.
2.3. Puri¢cation of synthetic S100A12
Analytical and preparative reversed phase-HPLC (RP-HPLC) were
performed on a Waters 600 HPLC system. Analytical HPLC was run
on a Vydac C-4 column (5 Wm, 4.6U150 mm, 300 Aî ) at a £ow rate of
1 ml/min and UV absorbance monitored at 214 nm. Preparative RP-
HPLC was run on a Waters C-4 column (5 Wm, 46U150 mm, 300 Aî )
at a £ow rate of 10 ml/min and UV absorbance monitored at 230 nm.
The crude product was then dissolved in 50% bu¡er B (0.09% TFA in
90% acetonitrile) and eluted using a gradient system of 25^75% bu¡er
B versus bu¡er A (0.1% aqueous TFA) over 50 min. Eluted fractions
containing pure S100A12 were identi¢ed by analytical RP-HPLC and
ESI-MS, pooled, lyophilised and stored at 378‡C.
2.4. MS
Mass analysis of all synthetic peptides was ¢rstly performed on a
PE-Sciex API-III triple quadrupole (Q) mass spectrometer equipped
with an ion-spray (pneumatically assisted electrospray) atmospheric
pressure ionisation source (ESI-MS). Samples were injected using a
syringe infusion pump at nmol concentrations at 20 Wl/min, coupled
directly to the ionisation source via a fused-silica capillary (75 Wm
i.d.U40 cm length). Sample droplets were ionised at a positive poten-
tial of 5 kV and entered the analyser through an interface plate and
subsequently through an ori¢ce (100 Wm diameter) at a potential of
80 V. Full scan spectra were acquired by scanning Q1 from m/z 500^
2000 Da with a scan step of 0.2 Da and a dwell time of 0.4 ms.
Calculated masses were obtained from the program MacBioSpec
(PE-Sciex). The data were recorded and processed using the Tune
2.5-FPU (PE-Sciex) and MacSpec 3.3 (PE-Sciex) programs on a Mac-
intosh computer.
2.5. Endoproteinase Glu-C digest
S100A12 was digested with endoproteinase Glu-C (Staphylococcus
aureus V8; EC 3.4.21.19) in 50 mM ammonium acetate (pH 4) with
an enzyme:substrate ratio of 1:50 (w/w) at 37‡C for 2 h. The crude
product was analysed by positive ion HPLC/MS with a declustering
potential of 50 V. Full scan mass spectra were acquired over the mass
range of 400^2000 Da with a scan step of 0.1 Da and a dwell time of
0.3 ms.
2.6. ESI-TOF mass spectrometry
Mass spectra were acquired using an ESI-TOF mass spectrometer
constructed at the University of Manitoba [20]. An acceleration volt-
age of 4 kV was used for TOF analysis. Samples were normally
electrosprayed from a stainless steel needle (i.d. 120 Wm) using a
typical £ow rate of 250 nl/min. The ESI interface conditions were
mild to minimise possible disruption of non-covalent complexes, i.e.
low capillary desolvation temperature and low declustering potential.
S100A12 was reconstituted to 1035 M and analysed in 5 mM ammo-
nium bicarbonate (pH 7.5). The ESI-TOF spectra were acquired over
the mass range of 500 to 4000 Da with an ion spray current of 0.1^0.2
WA.
2.7. Circular dichroism (CD)
Far UV CD spectra were obtained on a Jasco J-300 spectropolarim-
eter calibrated with (+)-10-camphorsulfonic acid at 25‡C using a 0.1
cm path length. S100A12 in 10 mM phosphate bu¡er (pH 7.4) was
analysed at a ¢nal constant concentration of 55 WM. The secondary
structure was estimated by analysis of the spectrum between 190 and
300 nm. Each spectrum represents the average of 10 scans. Mean
residue ellipticity [a]MR is expressed in ‡ cm2)/dmol). Experimental
estimates of the helical content were determined from [a]222 mea-
surements. The K-helix content was calculated using equations de-
scribed by Chen [21] where % K-helix = ([a]222/[a]max)U100% and
[a]max =339 500[13(2.57/n)] ; n = number of residues per chain. This
equation is used only as a qualitative estimate of peptide helicity.
2.8. Cell culture
Human THP-1 cell (ATCC TIB 202) monocytoid cells were rou-
tinely cultured at 37‡C in 5% CO2 in air in RPMI 1640 (Gibco, Grand
Island, NY, USA) supplemented with 2 mM L-glutamine (Flow Lab-
oratories, Irvine, Scotland, UK), 100 U/ml penicillin, 100 Wg/ml strep-
tomycin (Sigma, St. Louis, MO, USA) and 10% heated (56‡C, 30 min)
bovine calf serum (Hyclone Laboratories, Logan, UT, USA). The
medium was ¢ltered through Zetapor 0.2 Wm membrane (Cuno, Mer-
iden, CT, USA) to remove contaminating traces of endotoxin. Endo-
toxin levels in reagents and medium were 6 1 ng/ml by the chromo-
genic limulus amoebocyte lysate assay (Cape Cod Association Wood
Hole, MA, USA).
2.9. Chemotactic activity
THP1 cells (5U106/ml) suspended in human Hanks’ Balanced salt
solution (HBSS) bu¡er (Sigma)/0.1% bovine serum albumin (BSA)
were incubated with 5 WM calcein AM (Molecular Probes, Eugene,
OR, USA) for 15 min at 37‡C in 5% CO2 in air, washed twice with
HBSS and resuspended at 0.5U106/ml in RPMI/0.2% BSA. Assays
were performed using Neuro Probe MBA-96-well Chambers with
polycarbonate membrane pore size 8 Wm (Neuro Probe, Bethesda,
MD, USA). Various concentrations of synthetic S100A12 (1038 to
10313 M) diluted in RPMI/0.2% BSA (410 Wl) were placed in the lower
compartment and cells (300 Wl) in the upper compartment. The cham-
ber was incubated at 37‡C in an atmosphere of 5% CO2 in air for 120
min. The number of migrated cells attached to the underside of the
membrane was expressed by measuring calcein £uorescence at
ex = 485 nm and em = 530 nm using a CytoFluor0 multi-well plate
reader system (PerSeptive Biosystems, Framingham, MA, USA).
Fluorescence readings were converted to cell numbers by producing
a standard curve with calcein-labelled THP-1 cells. The correlation
between cell number and £uorescence was high (R = 0.97051). C5a
(1039 M) was used as a positive control in all experiments.
2.10. Electrophoresis
Sodium dodecyl sulphate^polyacrylamide gel electrophoresis (SDS^
PAGE) was performed using the Bio-Rad Mini Protean II electropho-
resis cell and a Tris/tricine bu¡er system according to standard pro-
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cedures (Bio-Rad handbook). Proteins were separated in a 10% gel
run at 100 V for 2 h and silver-stained.
3. Results and discussion
3.1. Total chemical synthesis of S100A12
Total chemical synthesis of human S100A12 was considered
the most time e⁄cient and simple means of producing su⁄-
cient quantities of the protein for functional analysis. In gen-
eral, solid-phase peptide synthesis, which was originally devel-
oped by Merri¢eld [22], is a facile and e¡ective route for the
rapid production of multi-mg quantities of peptides, small
proteins or enzymes for immunological, biochemical or struc-
tural studies [23,24]. The technique was successfully used to
synthesise many small proteins including fully active human
immunode¢ciency virus-1 proteinase [25,26], interleukin 8
[23,24] and phospholipase A2 [27]. Chemical synthesis may
also permit more accurate investigation of the structure^func-
tion relationships that may not be readily accomplished with
recombinant proteins because of the ease of incorporation,
during synthesis, of non-coded amino acids, £uorescent
probes or NMR-active nuclei on speci¢c residues.
The manual sequential chain assembly of human S100A12
(Fig. 1) was carried out by HBTU in situ neutralisation chem-
istry [18] using Boc/benzyl orthogonal protection. During the
stepwise chain assembly, amino acid coupling e⁄ciencies were
monitored by the quantitative ninhydrin assay [28] and the
average coupling yield was estimated as 99.6%. The assembly
generally proceeded well except for a notable ‘di⁄cult’ cou-
pling at valine-68. This required re-coupling as the symmetric
anhydride before continuation. Following sequential chain as-
sembly, side-chain deprotection and cleavage from the resin
was performed by treating with HF/p-cresol (9:1) for 1 h at
0‡C. S100A12 was readily puri¢ed from the lyophilised crude
cleaved product by C4 RP-HPLC using a linear 1%/min gra-
dient of 0^80% bu¡er B versus bu¡er A. Pure S100A12 eluted
in 49% B as a single symmetrical peak (Fig. 2A). The manual
synthesis a¡orded approximately 10 mg of material (s 98%
purity) in less than 4 weeks. The purity and integrity of syn-
thetic S100A12 was con¢rmed by ESI-MS, Glu-C digestion
and SDS^PAGE analysis. Like its porcine analogue [14],
S100A12 migrated on SDS^PAGE as an 8 kDa component
rather than at the expected 10.5 kDa (Fig. 2B). CaBPs often
have irregular mobilities on SDS^PAGE gels [14] and a more
accurate mass measurement was determined by ESI-MS. The
Fig. 1. Multiple sequence alignment of selected S100 proteins. S100A12 is shown bold. All sequences were obtained from the SWISS-PROT
protein sequence database and aligned using CLUSTAL W analysis [39]. Numbers at the end of the sequences indicate the total number of
amino acid residues, while boxed areas indicate regions of sequence homology. Predicted helical elements are indicated by a solid bar above
the sequences [28]. Calcium- and zinc-binding sites are indicated by hatched and double lines, respectively. Positions x, y, z, 3y, 3x, and 3z
correspond to calcium ligands. Abbreviations: Calb D9k, calbindin D9k ; h, human; m, murine, p, porcine, and b, bovine.
Fig. 2. Chemically synthesised human S100A12. A: C4 RP-HPLC.
B: lane 1: reference molecular mass markers of 8.1, 10.7, 14.4 and
16.9 kDa, respectively; lane 2: chemically synthesised human
S100A12. C: ESI mass spectrum of S100A12 shows protonated ion
species with charges 6+ to 13+ corresponding to an observed molec-
ular mass of 10 445.4 þ 0.8 Da (calculated mass 10 444.9 Da).
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observed molecular mass of 10 445.4 þ 0.8 Da, was within
experimental error (0.01%) of the calculated mass:
C471H744N126O142, 10 444.9 Da (Fig. 2C). The amino acid se-
quence of S100A12 was con¢rmed by digestion with endopro-
teinase Glu-C (S. aureus V8; EC 3.4.21.19) and analyses by
positive ion RP-HPLC/MS at a declustering potential of 80 V.
The separated peaks had m/z ion values which correlated well
with the expected and observed molecular weights of digest
fragments for the complete S100A12 amino acid sequence
(Table 1).
3.2. Ca2+/Zn2+ induced conformational changes
The structures of S100 proteins are highly conserved
[10,29,30] and secondary structures are predominantly helical.
Calcium and/or zinc regulate the function of several members
of the S100 family [41^43]. CD was used as a qualitative
gauge to investigate the potential conformational e¡ects of
these divalent cations on S100A12 secondary structure. The
CD spectra of S100A12 in several environments shown in Fig.
3 exhibit minima at 208 and 222 nm, characteristic of K-hel-
ical peptides and proteins. Using the method of Chen [21] the
apparent K-helical content of apo-S100A12 was estimated as
41%. The amount of calcium chosen for CD experiments was
similar to levels in extracellular biological £uid (2^5 mM). In
comparison to the apo form, the addition of 5 mM Ca2 ions
in the form of CaCl2 decreased helical content by 27% indi-
cating a conformational change upon calcium binding, and
agreeing well with previous observations with other CaBPs
[14]. In addition to the two calcium-binding domains,
S100A12 has a predicted His^Xaa^His^Xaa^His zinc-binding
motif from residues 85 to 89, which would also be expected to
adopt a helical structure (Fig. 1). In this motif the His residues
at positions n and n+4 are usually separated by a single helical
turn [9,31]. Addition of 5 mM ZnCl2 to apo-S100A12 only
increased K-helicity by 1%. Interestingly, when zinc was added
¢rst, followed by calcium, overall helicity (42%) was sub-
stantially greater than with calcium alone, suggesting that
zinc may antagonise conformational changes provoked
by Ca2. Similar results were also obtained with peptides
containing only the high-a⁄nity C-terminal EF-hand do-
main of S100A12 and its neighbouring zinc-binding site,
S100A12(54^91) and S100A12(38^91) (data not shown).
When the hydrophobicity of the solution environment was
increased by addition of 30% (v/v) 2,2,2-tri£uoroethanol
(TFE) in the absence of calcium or zinc ions, helicity in-
creased to 49%, with no increased e¡ect at higher concentra-
tions. This compared well with the expected maximal
S100A12 helicity of 52% predicted from sequence homology
with S100A6 [17].
3.3. S100A12 homodimerisation by ESI-TOF MS
Insights into macromolecular interactions of S100 proteins
are traditionally obtained using X-ray crystallography [32] or
NMR [16,17]. Although these techniques provide considerable
structural information, they are time consuming and require
multi-mg quantities of pure proteins. Recent developments in
ESI-MS provide signi¢cant advances to rapidly investigate
non-covalent interactions using nmol quantities of proteins
[33^35]. Information on the intrinsic propensity of S100 pro-
teins to dimerise provides valuable insight into the molecular
mechanisms by which speci¢c S100 proteins may interact
with, and alter the function of selective target proteins. A
pertinent example is the observation of S100A8 homodimers
by mild ESI-MS analysis [36].
ESI-TOF MS analysis is well suited for oligomerisation
studies as it requires low quantities of proteins and can ana-
lyse large complexes with relatively high m/z values, s 3000
[34] in a much shorter time frame than NMR or X-ray crys-
tallography studies which require relatively high protein sol-
ubility (mM) or good di¡racting crystals. Macromolecular
interactions may arise from at least four types of relatively
weak forces: ionic interactions, hydrogen bonds, the hydro-
phobic e¡ect or van der Waals forces. Their weak nature
makes most gas-phase complexes relatively fragile and gentle
ionisation conditions are required to minimise complex disso-
ciation [35]. Although ESI-MS satis¢es this criterion and can
now give insight into non-covalent interactions, caution must
Table 1
Endoproteinase Glu-C human S100A12 digest fragments observed by LC/MS analysis
Position Experimental mass Calculated mass S100A12 fragment sequence
1^4 489.3 489.28 TKLE(E)
5^8 526.2 526.24 (E)EHLE(G)
32^34 387.5 387.25 (E)LKQ(L)
68^84 1834.5 1834.02 (Q)VDFQEFISLVAIALKAA(H)
32^39 971.6 971.60 (E)LKQLLTKE(L)
40^55 1784.0 1784.00 (E)LANTIKNIKDKAVIDE(I)
56^65 1119.5 1119.52 (E)IFQGLDANQD(E)
67^72 764.3 764.33 (E)QVDFQE(F)
9^31 2631.4 2631.36 (E)GIVNIFHQYSVRKGHFDTLSKGE(L)
73^91 2148.2 2148.18 (E)FISLVAIALKAAHYHTHKE
Fig. 3. Far-UV CD spectra of S100A12. Spectra acquired in the
presence of 5 mM EDTA, -a- ; 5 mM CaCl2, -E- ; 5 mM ZnCl2,
-7- ; 5 mM CaCl2/ZnCl2, -U- ; and 30% (v/v) TFE, -O-. Protein
concentration was 55 WM S100A12 in 10 mM phosphate bu¡er, pH
7.4, and temperature was 25‡C.
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be taken to select experimental conditions which yield m/z
values representing non-covalent complexes in solution. Fail-
ure to observe a complex could be due to many factors, in-
cluding inappropriate ionisation conditions, i.e. high declus-
tering potential, pH, or solvent environment, making it
di⁄cult to use the technique as de¢nitive evidence against
oligomeric or non-covalent interactions. However, if suitable
mass spectrometric conditions are achieved, the chemical and
solvent parameters which potentially in£uence non-covalent
interactions can be studied with con¢dence [34,37].
In ESI-TOF MS experiments, human S100A12 (1035 M)
was reconstituted and analysed in 5 mM ammonium bicar-
bonate (pH 6.5). The ESI-TOF mass spectrum showed pro-
tonated ion species with charges of 7+ to 10+ corresponding
to the non-covalent S100A12 homodimer (20 890 Da); (Fig. 4)
with no other multimeric forms evident. The S100A12 mono-
mer contains no cysteine residues, so the formation of dimeric
structures must clearly result from non-covalent interactions.
The clear domination of dimers in the spectrum may indeed
indicate speci¢c interactions (Fig. 4).
3.4. Bioactivity
Bovine S100A12 is chemotactic for monocytes but because
S100 sequence homologues do not necessarily represent func-
tional homologues [38], human S100A12 was tested for che-
motactic activity. Chemically synthesised human S100A12
(10310 and 10312 M) was indeed chemotactic for human
monocytoid THP1 cells (Fig. 5). Importantly, the activity
was as potent as the classical chemoattractant, C5a, but oc-
curred at markedly lower molar concentrations. S100A12 over
the assayed concentration range produced a bell-shaped activ-
ity curve that is typical of all chemoattractants [38,44]. At
high levels and full receptor occupancy, the cells fail to
move because of the requirement for a concentration gradient
and low receptor occupancy [44]. Human neutrophils and
HL60 cells di¡erentiated to neutrophils also responded and
intraperitoneal injection of human S100A12 into mice elicited
an in£ammatory in¢ltrate (manuscript in preparation). The
activity of the synthetic human protein was approximately
2^3 orders of magnitude more potent than reported for the
native bovine protein tested using human monocytes [8]. Dif-
ferences in potency may be due to sequence di¡erences within
the two proteins, particularly within the hinge region located
between the EF-hands which is the chemotactic domain of
murine S100A8 [40].
4. Conclusion
Chemical synthesis was a rapid and e¡ective method of
producing multi-mg quantities of functionally active human
S100A12, a 10 kDa CaBP. Preliminary structural studies us-
ing CD analysis indicated a conformational change in the
presence of calcium, which was antagonised by zinc ions.
ESI-TOF MS analysis was used to study oligomerisation,
and m/z values corresponding to non-covalent S100A12
dimers predominated. If the native state of S100A12 is dimer-
ic, it may adopt a tertiary structure analogous to calcyclin and
psoriasin which form a non-covalent anti-parallel homodimer
[17], and this may provide insights into its functional form.
Results presented here demonstrate the utility of ESI-MS and
ESI-TOF MS for identifying non-covalent interactions. We
con¢rmed that human S100A12, like its bovine analogue [8],
was chemotactic for human monocytoid cells and signi¢cantly
more potent.
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tions of S100A12 (b). Control represents random migration of cells
toward RPMI/0.2% BSA (-a-). Positive migration of cells to the
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